Atamyo Therapeutics Submits CTA in Europe for ATA-100, Its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2I/R9
Company also appoints Sophie Olivier, M.D., Chief Medical Officer, joining co-founders Stephane Degove, Chief Executive Officer, and Isabelle Richard, Ph.D., Chief Scientific Officer Atamyo is a
Source: finanznachrichten.de